AP23846, a novel and highly potent Src family kinase inhibitor, reduces vascular endothelial growth factor and interleukin-8 expression in human solid tumor cell lines and abrogates downstream angiogenic processes.

@article{Summy2005AP23846AN,
  title={AP23846, a novel and highly potent Src family kinase inhibitor, reduces vascular endothelial growth factor and interleukin-8 expression in human solid tumor cell lines and abrogates downstream angiogenic processes.},
  author={Justin M. Summy and Jose G. Trevino and Donald P. Lesslie and Cheryl Baker and William Shakespeare and Yihan Wang and Raji Sundaramoorthi and Chester A. Metcalf and Jeffrey A. Keats and Tomi K. Sawyer and Gary E. Gallick},
  journal={Molecular cancer therapeutics},
  year={2005},
  volume={4 12},
  pages={1900-11}
}
c-Src is frequently activated in human malignancies, including colon, breast, and pancreatic carcinomas. Several recent studies have shown that activation of Src family kinases leads to tumor progression and metastasis by increasing cellular migration and invasion, promoting cell growth and survival, and deregulating expression of proangiogenic molecules. Therefore, selective inhibitors of Src are being developed for cancer therapy. In this study, we characterize the biological effects of the… CONTINUE READING
37 Citations
50 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 37 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 50 references

Similar Papers

Loading similar papers…